On Jun. 7, 2026, Roche announced that it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialise bexobrutideg (NX-5948), Nurix’s investigational Bruton’s Tyrosine Kinase (BTK) degrader. The collaboration encompasses a clinical development plan spanning B-cell malignancies, immunology and neurology. The addition of bexobrutideg complements Roche’s existing strengths in haematology and provides a cross-therapeutic opportunity to extend the pipeline’s reach in immunology and neurology.

Patients with B-cell–driven malignancies continue to face significant unmet need despite advances with BTK inhibitors and other therapies. In haematology, many patients with CLL ultimately experience disease progression due to acquired resistance mutations, incomplete pathway suppression, or intolerance that limits long-term use, and treatment options remain limited once patients relapse.

BTK-targeting assets represent a leading class within the expanding non-Hodgkin lymphoma (NHL) and CLL markets. The combined market is projected to reach $41 billion by 2031, with BTK inhibitors (BTKi) expected to remain the sales-leading class at approximately $19 billion. This growth is particularly evident in the CLL sector, which is forecast to increase from $12 billion in 2024 to $16 billion by 2035.

Bexobrutideg, an oral targeted BTK degrader, is planned for Phase 3 clinical trial initiation in summer 2026 for the second-line treatment of CLL. Available clinical data suggests it has the potential to become a best-in-class treatment option with higher efficacy and more favorable tolerability than established therapies. In addition, it offers the potential to overcome resistance mechanisms found in current standard-of-care BTK inhibitors. This collaboration creates a unique opportunity to leverage Roche’s industry-leading malignant haematology portfolio.

Under the terms of the agreement, Nurix will receive an upfront cash payment of USD 700 million and is eligible to receive development, regulatory and sales milestones for a potential total deal value of up to USD 2.3 billion. Development costs will be shared 40% by Nurix and 60% by Roche. The parties will equally split the profits and losses from U.S. commercialisation. Nurix and Roche will co-commercialise bexobrutideg in the United States across all indications. Outside of the United States, Roche will be responsible for commercialisation, with Nurix receiving royalties ranging from the low- to high-teens.